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Introduction
To make well-informed decisions about health care, we need to be able to compare and contrast research findings on the basis of the same outcomes. Core outcome sets (COSs) represent the minimum important outcomes that should be measured and reported in all research studies for a specific condition. The use of COSs will improve the quality of evidence used in health care decision-making, ultimately translating to improved health care for patients. For COSs to be successfully implemented, they need to be easily accessible to researchers and other key groups, developed using rigorous methods, and reported clearly. The Core Outcome Measures in Effectiveness Trials (COMET) Initiative was set up to help achieve this. The development and continued maintenance of the COMET database [1, 2] , through rigorous systematic reviews [3e7], means that COSs are now easily accessible to users of COSs. The COMET Handbook advocates the use of rigorous methods through an accumulation of current knowledge in the area of COS development and will be updated What is new?
Key findings
No core outcome set (COS) met all of the 12 criteria representing the 11 minimum standards assessed in this study (range 5 4e11 criteria, median 5 6 criteria).
Poor reporting often made it challenging to assess whether the minimum standards had been met.
What this adds to what was known?
This is the first application of Core Outcome Set eSTAndards for Development (COS-STAD) criteria to studies that have developed COSs and provides a baseline of cancer COS standards of development.
COS-STAD was not published until 2017; all included COS studies were carried out before this publication date. Therefore, this assessment is not a criticism of these studies or the study authors, but rather a baseline against which future comparisons of cancer COSs can be made.
What is the implication and what should change now?
This current review provides guidance on how to compare a published COS to the standards (Table 2 ). This will further facilitate users to assess whether a COS has been well developed.
This study identified the need to separate standard number 9 into two criteria, considering scoring process and consensus definition separately. We recommend this separation for future users of COS-STAD.
periodically to continue to inform good methodological practice in this area [8] . Furthermore, the Core Outcome SeteSTAndards for Development (COS-STAD) recommendations have been established to improve the methodological approach for developing COSs and help users to assess whether a particular COS has been developed using a reasonable approach [9] . Research in the area of COS development is becoming more prevalent, but it is still quite new; we would therefore expect improvements in methodological standards in the coming years. To be able to assess this, however, a baseline, against which we can compare future quality of COS development and measure improvements in methodological standards, is necessary. COSs are developed across a wide range of disease areas. Cancer is currently the disease area with the highest number of published COSs. Furthermore, cancer is a major cause of worldwide morbidity and mortality, has substantial variability in populations and treatments, and covers a wide range of diverse clinical areas. Treatments aim to cure the disease but are associated with multiple side effects; trials are commonly performed, and major clinical oncology organizations exist worldwide. It is essential to ensure that outcomes in cancer trials reflect issues of importance to patients and health care professionals through the use of well-developed COSs. The aim of this study was therefore to provide a baseline of cancer COS standards of development against which future comparisons can be made.
Methods

Identification of COS studies
As of the end of 2017, a regularly updated systematic review of COSs [3e7] had identified 307 published COSs for research studies covering a wide range of different health areas. Only COSs developed for cancer were eligible for inclusion in this evaluation.
Pilot study
COS-STAD contains 11 standards that are deemed to be the minimum design recommendations for all COS development projects [9] . The recommendations focus on three key domains: scope, stakeholders, and consensus process.
A pilot study was carried out to inform the process of assessment used in this study. One COS was randomly selected. Three of the authors (E.G., P.R.W., and J.J.K.) independently read the COS and made an assessment against each of the 11 criteria listed in Table 1 . Assessments were compared, and a discussion occurred between the three authors to define how the process should be applied. This included the criteria used for assessment and the sources of information that would be used to identify supporting information. Following this, a further five randomly selected COSs were independently assessed by two of the authors (E.G. and J.J.K.), and the process was further refined. Of note, it was agreed that criteria number 9 (''A scoring process and consensus definition is described a priori'') would be split into two for assessment purposes. It became apparent that in the five COSs assessed in the pilot study that a study team could describe an a priori definition for one of these only (e.g., provide a description of a scoring process but not provide a consensus definition or vice versa), resulting in different assessments for each part of this criterion and should therefore be assessed separately. Hereafter, they will be referred to as 9a (scoring process) and 9b (consensus definition). A total of 12 criteria were therefore assessed in this study, representing the 11 minimum standards.
Process
Two reviewers (E.G. and J.J.K.) independently assessed each of the cancer COSs against the 12 criteria of development. Each criterion was assessed as yes (meeting that standard), no (not meeting that standard), or unsure (it was unclear whether the criteria had been met). Further details of the assessment are described in Table 2 .
Verbatim text was extracted to support the assessment being made and to aid discussion. Assessments were compared, and a third reviewer consulted where there was uncertainty. P.R.W. and J.M.B. were consulted for methodological queries, and J.M.B. (surgical oncologist), for clinical queries. Where the development process was described across multiple articles for an individual COS, a global assessment was made for each of the standards.
Sources of information
Articles describing the development of the COS were eligible for providing supporting information for each of the standards. This included main study publications and protocols. The COMET database was not used as a source of information in this study as it is a secondary source of information (populated by the systematic reviews used in this study to identify cancer COSs) and does not contain any additional details necessary for this study.
Data analysis and presentation of results
The median and range were used to summarize the 12 criteria (representing the 11 minimum standards) met across all of the included cancer COS studies. Percentage frequencies were used to report the number of studies that met each standard.
Results
Forty-nine cancer COSs were included. An overview of the minimum standard assessments is provided in Table 3 , and by study in Appendix 1. No COS met all of the 12 criteria representing the 11 minimum standards assessed in this study (range 5 4e11 criteria, median 5 6 criteria).
Scope specification
All studies met all four standards for scope.
3.1.1. Standard number 1: the research or practice setting(s) in which the COS is to be applied All studies met this criterion: 40/49 (82%) stated that the COS was intended for use in clinical trials, 4/49 (8%) stated that the COS was intended for use in clinical research, two (4%) stated that it was intended for use in clinical trials and routine clinical practice, and three (6%) for research and routine clinical practice.
Standard number 2: the health condition(s) covered by the COS
All studies met this criterion. Five COSs were developed for cancer (nonspecific), and four specifically for complications of the treatments of cancer. Nine COSs were developed for prostate cancer, five for cancer of the colon and/ or rectum, and three for ovarian cancer. Two were developed for nonesmall cell lung cancer, two for Hodgkin's and non-Hodgkin's lymphomas, and two COSs were developed for acute myeloid leukemia. The remaining seventeen unique cancer COS areas are listed in Appendix 2.
Standard number 3: the population(s) covered by the COS
All studies met this criterion. In 10 of the cancer COSs, it was not explicitly stated that the COS was intended for an adult population only, but this was assumed because the cancer covered by the COS was an adult-only cancer (e.g., prostate cancer). Further assumptions were made for an additional thirteen COSs that related to cancers that may occur in children and adults but did not make any statement about the population that the COS was intended. These 13 COSs were deemed to be implicitly for adults only because they did not refer to children specifically. A scoring process and consensus definition was described a priori 10 Criteria for including/dropping/adding outcomes were described a priori
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Care was taken to avoid ambiguity of language used in the list of outcomes
Abbreviations: COS-STAD, Core Outcome SeteSTAndards for Development. 3.1.4. Standard number 4: the intervention(s) covered by the COS All studies met this criterion. Where the authors referred to ''evaluating treatments,'' ''cancer treatments,'' or a COS for ''all trials,'' we took this to mean all interventions. Twenty-six (53%) COSs were developed for all/any interventions, eight (16%) for drug interventions, four (8%) for procedures, three (6%) for surgical interventions, two (4%) for screening, and the remaining six (12%) were for other specific interventions (preoperative treatment strategies, adjuvant treatment, larynx preservation strategies, vaccination, exercise, and compression interventions).
Stakeholders involved
Eight (16%) studies met all three standards for stakeholders involved.
Standard number 5: those who will use the COS in research
Thirty-six studies (74%) met this standard. Assumptions were made based on the author affiliations (where it was clear that the authors contributed to the COS development process) or from the participant list affiliations when these were provided, for 10 COSs. These 10 did not explicitly An explicit statement that this was not considered.
Abbreviations: COS-STAD, Core Outcome SeteSTAndards for Development. a ''a priori'' as assessed by inclusion in a protocol or when stated ''a priori'' in the study report without a protocol to verify this (we have taken this at face value).
b Clinicians, physicians, clinical investigators, and medical faculty were all different descriptors used for this in the cancer COS articles. state that researchers were included as participants, but we assumed their inclusion when research institutions were listed as affiliations. Seven studies (14%) did not state that those who will use the COS in research were involved in the COS development and there was not enough evidence to support an assumption being made; therefore, these were categorized as unclear. Examples include where it was not clear that the authors were the panel/participants involved (and no other statement was made in relation to stakeholders), participants were described as conference participants, but their backgrounds were not described or they were described as ''experts'' without any further description.
Six studies (12%) did not meet this standard. In these instances, the stakeholders involved were clearly described and did not include those who will use the COS in research.
Standard number 6: health care professionals with experience of patients with the condition
Thirty-five studies (71%) clearly met this standard. Assumptions were made for eight COSs based on the author affiliations (where it was clear that the authors are the group who developed the COS) or from the participant list affiliations when these were provided. These eight did not explicitly state that health care professionals (HCPs) were included as participants, but we assumed their inclusion when clinical care settings were listed as affiliations.
Eight (16%) did not state explicitly that HCPs were involved in the COS development and there was ambiguity in the description provided; these were, therefore, categorized as unclear. Examples echoed those given for standard number 5.
Six studies (12%) did not meet this standard. In these instances, the stakeholders involved were clearly described and did not include HCPs in the process.
Standard number 7: patients with the condition or their representatives
Thirteen studies (27%) met this standard. Eight studies described including patient advocates or representatives, and five included patients themselves. The number of patients in six of these studies was not reported. The percentage of patients with the condition or their representatives in the remaining seven studies ranged from 9% to 68% in studies with mixed participants.
Thirty-five studies (71%) did not meet this standard. In these instances, the stakeholders involved were clearly described and did not include patients in the process. It was unclear in one study whether patients were included as participants were described as conference delegates without any further description.
Consensus process
Two studies (4%) met all four standards [five criteria] for the consensus process.
Standard number 8: the initial list of outcomes considered both health care professionals' and patients' views
Eight studies (16%) met this standard. Two of these five included patient-reported outcome (PRO) data (i.e., studies that have collected data from patients using a patientreported outcome measure [PROM]) as well as trial data, and therefore on face value have included the patient perspective in the process.
Five studies (10%) did not clearly state whose views were considered when generating the initial list and so, therefore, have been categorized as unclear. One of these studies included PROM items in the review (PROM items only not PRO data). Patients may or may not have been involved in the PRO development, but it was beyond the scope of this study to research PROM development; we cannot therefore say if they considered patients' views.
Thirty-six studies (74%) did not meet this standard and did not consider both HCPs' and patients' views when generating the initial list of outcomes used in the COS development. These studies considered trial data, clinical trials literature, or clinical guidelines only (hence did not consider patients' views).
Standard number 9a: a scoring process was described a priori
Five studies (10%) met this standard. It was unclear whether the remaining 44 (90%) met this standard. Ten studies described a scoring process, but it was not clear whether this process was determined a priori; 28 studies did not describe specific methods relating to scoring, and six studies did not describe the methods used at all.
Standard number 9b: a consensus definition was described a priori
Six studies (12%) met this standard. It was unclear whether this standard was met for the remaining 43 (88%). In 26 studies, it was unclear whether the consensus definition was defined a priori; eleven studies did not describe a process of consensus and therefore did not provide a definition, and the remaining six studies did not describe their consensus methods at all.
3.3.4. Standard number 10: criteria for including/dropping/adding outcomes were described a priori Two studies (4%) met this standard. It was unclear whether this standard was met for the remaining 47 studies (96%). The detail of all three elements of this standard was not clearly described in six studies, and for two studies that did describe this process, it was not possible to assess the a priori element of this criterion. Thirty-three studies had no description of this process, and six did not describe their methods overall, making it impossible to assess whether this criterion had been considered.
3.3.5. Standard number 11: care was taken to avoid ambiguity of language used in the list of outcomes Five studies (10%) met this criterion. In one study, the outcomes were formulated with examples in parentheses for some PROs; and in another study, the patient representatives received a glossary of terms before completing the survey. Although this information is limited as COS-STAD is being applied retrospectively here, we have interpreted this as some consideration of the language used to describe outcomes. This criterion was clearly met in the other three studies, where the questionnaires were assessed, by patients, for face validity and comprehension before use.
For 44/49 studies (90%), there was no evidence that care was taken to avoid ambiguity of language, and therefore it was unclear whether they met this criterion.
Discussion
This is the first application of the COS-STAD criteria to studies that have developed COSs. Forty-nine cancer COSs were included. No COS met all of the minimum standards, with most studies meeting half of the standards. However, COS-STAD was not published until 2017, which was after all of these studies started. Therefore, this assessment is not a criticism of these studies or the study authors, but rather a baseline against which future comparisons can be made. Furthermore, this current review provides guidance on how to compare a published COS to the standards (Table 2 ). This will further facilitate users to assess whether a COS has been well developed.
Standards in the scope domain were well met. One explanation for this could be that these scope criteria are synonymous with the ''PIC'' part of the PICO format that is often used to formulate a research question [10] . For the purposes of this study, there was an assumption that a COS was developed for adults only unless stated otherwise. This was deemed to be clinically relevant for cancer COSs, and consideration should be given to other disease areas and whether the same assumption is correct. When assessing standards in the scope domain, we observed that multiple COSs were developed for some cancers, for example, nine COSs have been developed for prostate cancer alone. At times, this may reflect unnecessary duplication, but often they had relevant and appropriate differences in scope; for example, differences in stage or type such as advanced or localized cancer. COS-STAD can be used as a tool to help users of COSs to assess whether a COS has been well developed. Users will need to use their own judgment regarding the applicability of the COS (scope) for the purpose they require [9] .
Most COS studies did include those who will use the COS in research and HCPs in the development process, whereas just over a quarter included patients or patient representatives in the process. This is reflective of COSs in general and is not a methodological problem specific to cancer. Recent research has shown an improvement in patient participation in more recently published COSs [6, 11] . Although thirteen studies did include patients in COS development, there is still great variability in the level of participation of patients in COS development. This also needs to be taken into account when deciding if a COS was well developed.
The consensus process standards were the most difficult to compare against, particularly those that required an assessment of being specified a priori. Only four studies stated that they had a protocol, of which two were published and one we were able to obtain from study authors. In the remaining studies, because we were applying this retrospectively, we took it at face value when the COS report stated that something was specified a priori because we were unable to verify this in a protocol. Although making the protocol publicly available for a COS development study was not agreed on as a COS-STAD minimum standard, it was suggested that the availability of a protocol would ensure that the methods are explicitly documented before the COS development project starts, thus promoting research integrity and transparency of the finalized COS. This will make it easier for users to assess the COS against COS-STAD for future studies.
This study identified the need to consider the scoring process and consensus definition separately. We recommend this separation for future users of COS-STAD. With regard to criteria 9a (scoring), an observation was that in those that did not meet this standard, the method of development used for consensus in all of these studies was some form of meeting or workshop to decide on the COS, but detailed description of what was done at those meetings was missing. Further consideration is needed about the applicability and suitability of this criterion for all methods that might be used for COS development.
Standard number 10, the criterion for including/dropping/ adding outcomes, was only met by two studies. The a priori part of the assessment was unclear for a further two studies, but the majority did not mention anything about this process or did not describe it in sufficient detail to be able to assess whether this criterion was met. This suggests that perhaps COS developers do not fully understand the implications or importance of this aspect of the development process, and detail might be lacking as it might be considered too much information for publication. It should be noted that a lack of reporting of methods does not necessarily mean that these methodological aspects were not considered. This standard is also reflected in the Core Outcome Set-STAndards for Reporting (COS-STAR) as a reporting requirement [12] . However, COS-STAR was not published until 2016, which is after most of these included COS studies were published. It is therefore unrealistic to expect these reporting standards to be implemented in these studies, so it is to be hoped that evidence of consideration of this criterion (and indeed the other standards) will be included in study reports in the future.
COS-STAD focusses on the main design principles for COS development, whereas COS-STAR is exclusive to the reporting of COS studies. As already highlighted, issues with reporting were one of the main limitations of this study as it made it difficult, sometimes impossible, to assess consideration of the COS-STAD standards. We did obtain protocols when it was stated that a protocol was available, but this was very few. As such, we were unable to distinguish development plans from poor final reporting. Furthermore, this meant that assumptions were sometimes made to enable a judgment to be made. Another limitation was that the studies being assessed were published before COS-STAD and therefore could not have been informed by the development standards. Another potential limitation is that we identified cancer COSs from existing systematic reviews of COSs and did not conduct a separate search. To address this potential limitation, the list of COSs was reviewed by a relevant expert (J.M.B.) for completeness. The inclusion of cancer/COS methodology experts was a further strength of this study, as was the independent dual extraction and assessment of data.
This study aimed to provide a baseline of cancer COS standards of development against which future comparisons can be made. With the exception of scope specification, there is much need for improvement. Poor reporting made it challenging to assess whether the minimum standards had been met for all stakeholder involvement and consensus process standards. With the publication of methodological evidence [13, 14] and guidance [8, 9, 15] , as well as reporting standards [12] , improvement is expected over time. 
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